Mostrar el registro sencillo del ítem

dc.contributor.authorFernández Colino, Alicia
dc.contributor.authorQuinteros, Daniela A.
dc.contributor.authorGirotti, Alessandra
dc.contributor.authorPalma, Santiago D.
dc.contributor.authorArias Vallejo, Francisco Javier 
dc.date.accessioned2018-12-18T08:04:12Z
dc.date.available2018-12-18T08:04:12Z
dc.date.issued2017
dc.identifier.citationMolecular Pharmaceutics, 2017, 14 (12), pp 4498–4508es
dc.identifier.issn1543-8384es
dc.identifier.urihttp://uvadoc.uva.es/handle/10324/33506
dc.descriptionProducción Científicaes
dc.description.abstractThis work focuses on improving the effectiveness of current therapies against glaucoma by incorporating self-assembled polymers into the ophthalmic formulation. To that end, we first studied the influence of the dispersing medium on the mechanical performance of self-assembling elastin-like (EL) and silk-elastin-like (SEL) hydrogels by conducting rheological tests. These polymers were subsequently incorporated into the antiglaucoma formulation, which contains timolol maleate (TM) as active ingredient, and in vivo tests, namely adhesion tests and intraocular pressure measurements (IOP), were performed in New Zealand rabbits. An enhanced reduction in IOP due to the presence of the polymers was observed. Moreover, differences in the effectiveness between both EL- and SEL-hydrogels, which can be explained on the basis of the different rheological properties displayed by these two systems, were also encountered. The results point to the potential of this system as a basis for the development of an ophthalmic formulation against glaucoma.es
dc.format.mimetypeapplication/pdfes
dc.language.isoenges
dc.publisherAmerican Chemical Societyes
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.subject.classificationGlaucomaes
dc.subject.classificationElastinaes
dc.subject.classificationElastines
dc.titleSelf-Assembling Elastin-Like Hydrogels for Timolol Delivery: Development of an Ophthalmic Formulation Against Glaucomaes
dc.typeinfo:eu-repo/semantics/articlees
dc.rights.holder© 2017 American Chemical Societyes
dc.identifier.doihttps://doi.org/10.1021/acs.molpharmaceut.7b00615es
dc.relation.publisherversionhttps://pubs.acs.org/doi/abs/10.1021/acs.molpharmaceut.7b00615es
dc.peerreviewedSIes
dc.description.projectEuropean Social Fund (ESF) and European Regional Development Fund (ERDF)es
dc.description.projectComisión Europea (proyectos NMP-2014-646075, HEALTH-F4-2011-278557, PITN-GA-2012-317306, y MSCA-ITN-2014-642687)es
dc.description.projectMinisterio de Economía, Industria y Competitividad (Projects MAT2015-68901-R, MAT2016-79435-R and MAT2016-78903-R)es
dc.description.projectJunta de Castilla y León (programa de apoyo a proyectos de investigación – Ref. VA244U13 y VA313U14)es
dc.description.projectCIBER-BBN, Instituto de Salud Carlos III a través de la "Red de Medicina Regenerativa y Terapia Celular de Castilla y León", con el apoyo del “Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) y la Universidad Nacional de Córdoba (Argentina)es


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem